ArticleFrontiers in oncology2026
Comparative clinical and prognostic significance of integrin αvβ3, αvβ5, and αvβ6 in osteosarcoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Integrins are involved in extracellular matrix interactions and tumor progression, but the comparative clinical relevance of αvβ3, αvβ5, and αvβ6 in osteosarcoma remains unclear. Methods: This retrospective cohort included 193 patients with histologically confirmed osteosarcoma and available formalin-fixed, paraffin-embedded tumor specimens, evaluable immunohistochemical staining, and follow-up data. Corresponding hematoxylin and eosin-stained sections were reviewed to identify viable osteosarcoma-containing regions. H-score assessment for αvβ3, αvβ5, and αvβ6 was restricted to morphologically identifiable viable osteosarcoma cells, while non-tumoral staining was excluded. Two observers blinded to clinical data independently evaluated staining intensity and the percentage of positive tumor cells. Median H-scores were used for Kaplan-Meier curve visualization, whereas H-scores were modeled continuously in Cox regression analyses. Event-free survival (EFS) and metastasis-free survival (MFS) were analyzed using Kaplan-Meier and Cox models adjusted for age, sex, and tumor necrosis rate. MFS analyses included 183 patients without metastatic disease at baseline. Exploratory combined-expression analyses were also performed. Results: All three integrins showed heterogeneous expression in osteosarcoma tissues. αvβ3 expression was significantly higher in patients who developed metastatic events during follow-up, whereas αvβ5 and αvβ6 were not associated with metastatic events. High αvβ3 expression was associated with poorer EFS (p = 0.003) and MFS (p = 0.001). In multivariable models, continuous αvβ3 H-score remained associated with poorer EFS (HR, 1.011; 95% CI, 1.005-1.017; p < 0.001) and MFS (HR, 1.012; 95% CI, 1.006-1.019; p < 0.001). αvβ5 and αvβ6 were not significantly associated with survival, and combined-expression analyses did not provide clear additional prognostic discrimination. Conclusions: Among the three αv-containing integrins examined, αvβ3 showed the most consistent association with metastatic events during follow-up and poorer EFS and MFS. Its long-term prognostic relevance and clinical applicability require validation in larger independent cohorts with longer follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.